Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DSGN vs ERAS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ERAS Captures Overall Composite Edge (36.9 SELL vs 49.9 HOLD), While DSGN Leads 2–1 on Growth & Valuation Pillars

ERAS Overall Winner 6-Pillar Tally: DSGN 2 – 1 ERAS (3 Tie) Matrix Metrics: DSGN 3 – 2 ERAS

As of Nov 16, 2026, Erasca, Inc. (ERAS) captures the overall head-to-head institutional edge over Design Therapeutics, Inc. (DSGN) on higher Unified Composite conviction (36.9/100 SELL vs. 49.9/100 HOLD) after splitting the core matrix 2–3 (led by Options & Positioning), while DSGN wins 2–1 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus ERAS at $14.95 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. ERAS 36.9/100 SELL), ERAS captures the overall institutional head-to-head verdict (2–3 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile ERAS is in a Breakdown options structure phase (RSI 51.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DSGN vs ERAS
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $10.53 · SMA50: $11.59
ERAS NASDAQ Head-to-Head Winner
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$14.95
-4.57% 1D
Market Cap $5.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.31β · 81% Vol
Unified Composite Score
36.9 / 100 SELL
Tech 15.0 Fund 47.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.6 · SMA20: $14.91 · SMA50: $14.94

6-Pillar Scorecard Institutional Category Breakdown (DSGN 2 – 1 ERAS)

Columns: Metric · DSGN · ERAS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $33,000 N/A
Market Cap $677.5M $5.5B
3. Profitability & Quality DSGN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -36.9% -48.7%
4. Balance Sheet & Cash Flow DSGN
Cash Generation (TTM) -$59M -$252M
Cash Flow Margin N/A N/A
Net Cash / Leverage $13M Net Cash $2.2M Net Debt (0.12x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ERAS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 92.0% (13th %ile) 89.2% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DSGN (3) vs ERAS (2)
Institutional Metric DSGN ERAS Criterion Row Edge
Market Capitalization
Scale
$677.5M $5.5B Larger Scale ERAS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-36.9% -48.7% Higher ROE DSGN
52-Week Range Position
Momentum
30% ($7–$17) 57% ($2–$24) Stronger Trend ERAS
Beta / 30D Volatility
Risk Regime
1.32β · 61% Vol 2.31β · 81% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 36.9 / 100 (SELL) Higher Composite DSGN
Trailing 12M Revenue (USD)
Operating Scale
$33,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$59M ($13M Net Cash) -$252M ($2.2M Net Debt (0.12x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ERAS +15.2 pp
DSGN: -3.59% · ERAS: +11.61%
3M Horizon ERAS +17.48 pp
DSGN: -34.91% · ERAS: -17.43%
6M Horizon ERAS +52.62 pp
DSGN: -7.1% · ERAS: +45.52%
1Y Horizon ERAS +447.6 pp
DSGN: +40.79% · ERAS: +488.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs ERAS. Trailing 12-month operating profitability (DSGN 0.0% vs ERAS 0.0%) and valuation multiples (DSGN N/M vs ERAS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M
ERAS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-48.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ERAS BREAKDOWN
87d in phase · OBV NEUTRAL
Current IV 89.2%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ERAS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ERAS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DSGN vs ERAS Key Questions & Quantitative Answers

As of Nov 16, 2026, Erasca, Inc. (ERAS) captures the overall head-to-head institutional edge over Design Therapeutics, Inc. (DSGN) on higher Unified Composite conviction (36.9/100 SELL vs. 49.9/100 HOLD) after splitting the core matrix 2–3 (led by Options & Positioning), while DSGN wins 2–1 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus ERAS at $14.95 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. ERAS 36.9/100 SELL), ERAS captures the overall institutional head-to-head verdict (2–3 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile ERAS is in a Breakdown options structure phase (RSI 51.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DSGN and ERAS split Growth & Scale metrics: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ERAS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DSGN generates $33,000 in USD-normalized revenue versus N/A for ERAS. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ERAS.

DSGN and ERAS trade at balanced relative valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ERAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus ERAS (-48.7% ROE) capital efficiency.

In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, ERAS carries 89.2% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.31β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.